Latest receivables for 4111.TWO: $380M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Chi Sheng Pharma & Biotech , Ltd (4111.TWO) currently reports a receivables of $380M as of June 2026. That compares with $380M in the prior-year period — down 2.1% year over year. Use the charts on this page to explore Chi Sheng Pharma & Biotech , Ltd's receivables history and peer comparisons.
Chi Sheng Pharma & Biotech , Ltd's receivables decreased from $380M to $380M — a 2.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Chi Sheng Pharma & Biotech , Ltd reported $380M in receivables as of June 2026. That compares with $380M in the prior-year period — down 2.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current receivables of $380M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Chi Sheng Pharma & Biotech , Ltd, and consider following 4111.TWO for alerts when major investors trade the stock.